FDA did­n't con­duct any new in­spec­tions of Covid-19 vac­cine man­u­fac­tur­ing fa­cil­i­ties pri­or to is­su­ing EUAs

4 years ago
FDA+
Coronavirus

GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

4 years ago
News Briefing

Med­able trots its way to uni­corn sta­tus amid vir­tu­al tri­al craze. Is a pub­lic de­but next?

4 years ago
Financing

Eli Lil­ly scraps a tau pro­gram for Alzheimer’s, echo­ing past fail­ures and cast­ing doubt on en­tire ap­proach

4 years ago
R&D

Covid-19 roundup: Mer­ck shares mol­nupi­ravir with a UN-backed non­prof­it; GSK halts Covid-19 re­search on mon­o­clon­al ...

4 years ago
Coronavirus

Take­da swoops in and scoops up a cell ther­a­py start­up in buy­out deal, ex­pand­ing on­col­o­gy pipeline

4 years ago
Deals
R&D

With Covid-19 vac­cine in lim­bo, Chi­na's Fo­s­un inks $628M deal for a Pre­vnar 13 ri­val

4 years ago
Deals
China

Ex­clu­sive: A year in­to his role, Ipsen's CBO is on a $3B mis­sion to get the com­pa­ny 'back on the right track'

4 years ago
People
Pharma

Feds ar­rest pop­u­lar Twit­ter day trad­er over al­leged 'pump and dump' scheme

4 years ago
People

Har­poon CEO re­signs in wake of dwin­dling mar­ket cap and slid­ing stock price

4 years ago
People
Pharma

A qui­et car­dio up­start makes some noise, get­ting $300M from Bain and div­ing deep in­to the clin­ic — with some re­al ...

4 years ago
Financing

An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

4 years ago
R&D

FDA's vac­cine ad­comm votes al­most unan­i­mous­ly in fa­vor of Pfiz­er's Covid-19 vac­cine for younger chil­dren

4 years ago
FDA+
Coronavirus

Mod­er­na chips in fur­ther on African vac­cine sup­ply — but ad­vo­cates are call­ing for even more

4 years ago
Manufacturing

An Alzheimer's dark­horse fails its first big tri­al, but of­fers hope for a long-over­looked hy­poth­e­sis

4 years ago
R&D

ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for ...

4 years ago
News Briefing

As pres­sure to share tech­nol­o­gy mounts, BioN­Tech se­lects Rwan­da for lat­est vac­cine site

4 years ago
Manufacturing

No­var­tis dumps AveX­is pro­gram for Rett syn­drome af­ter fail­ing re­peat round of pre­clin­i­cal test­ing

4 years ago
R&D
Cell/Gene Tx

Bausch Health’s Sal­ix pi­lots study to shine light on chron­ic liv­er dis­ease and push back on stereo­types

4 years ago
Pharma
Marketing

Eli Lil­ly toss­es a mar­quee pain drug and hits the gas on Alzheimer’s — as Bio­gen’s suf­fer­ing opens mar­ket to ...

4 years ago
R&D

Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

4 years ago
Deals
Cell/Gene Tx

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

4 years ago
China
In Focus

Mozart Ther­a­peu­tics makes its of­fi­cial de­but, jump­ing in­to the hot Treg R&D field with some big-name in­vestors ...

4 years ago
Financing
Startups

The biotech be­hind Glax­o­SmithK­line's PD-1 just scored a $250M cash deal for roy­al­ties

4 years ago
Deals
First page Previous page 622623624625626627628 Next page Last page
A service from the Financial Times